Peptide Stacking with GLP-1s: What People Are Combining with Ozempic and Mounjaro

We corrected source identifiers and replaced a misidentified Vanderbilt cohort with the actual SEMALEAN study. We also removed unsupported claims about prescribing patterns, combination benefits, and clinical protocols.

Weight loss, gastrointestinal symptoms, and changes in skin appearance prompt questions about adding other products to GLP-1 treatment. A plausible mechanism is a reason to investigate a combination; it does not establish a benefit or a safe treatment protocol.

The relevant question is whether the specific combination has been evaluated for the outcome and population being discussed. Evidence from separate studies of separate compounds cannot answer that question.

The cited SEMALEAN study was a prospective semaglutide study, not the 1,809-patient Vanderbilt comparison previously described here. It enrolled 115 people with obesity; 106 completed follow-up. Lean mass declined during the first seven months and then stabilized, while handgrip strength improved by twelve months.

It did not test adding CJC-1295, ipamorelin, or tesamorelin. Its findings also illustrate why a lean-mass change cannot automatically be described as an equivalent loss of muscle function.

The 2025 orthopaedic systematic review included 35 preclinical studies and one clinical report within a search ending in June 2024. More recent small human reports exist, as discussed in our BPC-157 evidence review.

That is not evidence that BPC-157 prevents nausea, constipation, or other gastrointestinal effects during GLP-1 treatment. Calling the human literature entirely absent was too broad; treating the animal findings as a reason to recommend this combination was also unsupported.

The cited 2014 randomized trial enrolled 50 adults with HIV and abdominal fat accumulation. It assessed visceral and liver fat over six months. It did not test a GLP-1 combination or establish a treatment for fatty liver in the general population.

Visceral-fat reduction is not the same endpoint as preserving strength during GLP-1-associated weight loss. The trial cannot establish that adding a growth-hormone-releasing drug supplies that benefit.

The MOTS-c exercise paper and GHK-Cu review cited below provide biological context. They do not establish that adding these products to a GLP-1 medicine improves metabolic function or prevents loose skin. Human observations of an endogenous peptide are different from trials administering it. Topical cosmetic findings cannot establish the effects or safety of injections.

Claims that these are established prescribing patterns, or that one is the most effective or most logical stack, were not supported by the cited sources and have been removed.

Persistent gastrointestinal symptoms, difficulty eating adequately, or changes in strength deserve a discussion with the prescriber. Nutrition and activity plans should account for health conditions and treatment tolerance.

For any proposed additional medicine, ask what study tested that particular combination, what outcome improved, and what harms were measured. The sources reviewed here do not establish a self-directed wellness-peptide stacking protocol.